for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cipla Ltd

CIPL.NS

Latest Trade

485.50INR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

389.55

 - 

586.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
485.50
Open
--
Volume
--
3M AVG Volume
65.05
Today's High
--
Today's Low
--
52 Week High
586.00
52 Week Low
389.55
Shares Out (MIL)
806.11
Market Cap (MIL)
389,084.30
Forward P/E
21.53
Dividend (Yield %)
0.62

Next Event

Cipla Ltd Institutional Investor Meeting

Latest Developments

More

Cipla Says U.S. FDA Inspection Ends With 4 Observations

Venus Remedies Announces Sale Of Elores To Cipla In India

Cipla Announces Launch Of Daptomycin For Injection

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cipla Ltd

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

Industry

Biotechnology & Drugs

Contact Info

Mumbai Central

+91.22.24826000

https://www.cipla.com/

Executive Leadership

Yusuf K. Hamied

Non-Executive Chairman of the Board

Umang Vohra

Global Chief Executive Officer, Managing Director, Additional Director

Samina Vaziralli

Executive Vice Chairman of the Board

M. K. Hamied

Non-Executive Vice Chairman of the Board

Kedar Upadhye

Global Chief Financial Officer

Key Stats

2.30 mean rating - 40 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

142.8K

2018

147.5K

2019

163.6K

2020(E)

171.8K
EPS (INR)

2017

12.500

2018

18.460

2019

18.930

2020(E)

21.925
Price To Earnings (TTM)
23.60
Price To Sales (TTM)
2.32
Price To Book (MRQ)
2.49
Price To Cash Flow (TTM)
12.96
Total Debt To Equity (MRQ)
22.81
LT Debt To Equity (MRQ)
20.15
Return on Investment (TTM)
8.42
Return on Equity (TTM)
6.85

Latest News

Latest News

Indian shares end higher; Cipla top gainer on quarterly beat

Indian shares ended higher on Wednesday, with the broader NSE index breaching the 12,000 level for the first time since June 6 in intraday trade, helped by private banks and information technology companies.

BUZZ-India's Cipla rises after U.S. FDA closes inspection at Goa unit

** Shares of generic drugmaker Cipla Ltd rise as much as 3.41 pct to 538.75 rupees, their highest in a fortnight

Cipla third-quarter profit falls as lean India sales, tax cost weigh

Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic market.

Sensex, Nifty end higher for fifth session

Indian shares ended higher for a fifth straight session on Wednesday, with gains across most verticals, as investor sentiment was buoyed by a slew of upbeat quarterly results ahead of a key central bank policy meet which concludes on Thursday.

India's Cipla Q3 profit falls, lags estimate

Cipla Ltd, India's second-biggest generic drugmaker by market capitalisation, reported a 17.1 percent fall in third-quarter profit on Wednesday, hurt by higher tax expenses.

BUZZ-India's Cipla hits near 5-month low on Q2 profit miss

** Shares of Cipla Ltd fall as much as 7.73 pct to 560.2 rupees, lowest since June 12

Cipla warns of headwinds in second half after second-quarter profit miss

Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of analysts' estimates.

India's Cipla Q2 profit dips nearly 11 pct, misses estimate

Drugmaker Cipla Ltd posted a nearly 11 percent fall in second-quarter profit on Monday, much lower than analyst expectations.

BUZZ-India's Cipla hits near 9-mth high on Q1 profit beat

** India's third-largest drugmaker by market capitalisation Cipla Ltd's shares rise as much as 4.7 pct to 662.5 rupees, its highest since Nov 2017

Cipla first-quarter profit trumps estimates on strong domestic growth

Indian drugmaker Cipla Ltd posted quarterly profit well above analysts' expectations, helped by strong growth in the domestic market.

India's Cipla Q1 profit trumps estimates

Cipla Ltd, India's third-largest drugmaker by market capitalisation, posted on Wednesday a more than 10 percent rise in its first-quarter profit, well above analysts' expectations.

MEDIA-India's Cipla plans acquisitions to enter new therapies, boost Africa business - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

BUZZ-India's Cipla posts biggest intraday gain in over 3 months on Q4 profit

** Cipla Ltd rises as much as 7.8 pct to 564.90 rupees - posts biggest intraday pct gain since Feb 8

Cipla posts fourth quarter profit, misses estimates

Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

India's Cipla posts Q4 profit

Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.

BRIEF-India's Cipla Ltd Posts March Qtr Consol Profit

* MARCH QUARTER CONSOL NET PROFIT 1.79 BILLION RUPEES VERSUS LOSS OF 617.9 MILLION RUPEES LAST YEAR

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-India's Cipla Gets Final Nod For Generic Vazculep, Others

* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up